China SXT Pharmaceuticals (SXTC) Non-Current Debt (2019 - 2025)
China SXT Pharmaceuticals (SXTC) recorded quarterly Non-Current Debt of $73102.0 in Q3 2025, down 24.06% quarter-over-quarter from $96264.0 in Q1 2025, and down 36.62% on a YoY basis from $115344.0 in Q3 2024.
China SXT Pharmaceuticals (SXTC) Non-Current Debt (2019 - 2025) Analysis & Trends
China SXT Pharmaceuticals' Non-Current Debt history runs 6 years deep, the most recent figure standing at $73102.0 for Q3 2025.
- In Q3 2025, Non-Current Debt fell 36.62% year-over-year to $73102.0; the TTM figure through Sep 2025 stood at $73102.0 (down 36.62% YoY), while the FY2025 annual figure was $96264.0, down 17.81% from the prior year.
- Non-Current Debt was $73102.0 for Q3 2025 at China SXT Pharmaceuticals, down from $96264.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $117862.0 in Q1 2023 to a low of $6292.0 in Q1 2021.
- Historically, Non-Current Debt has averaged $90366.9 across 4 years, with a median of $106575.0 in 2023.
- The sharpest annual moves came in 2021 and 2024: Non-Current Debt slumped 82.77% in 2021, then advanced 8.23% in 2024.
- A 4-year view of Non-Current Debt shows it stood at $6292.0 in 2021, then surged by 1593.82% to $106575.0 in 2023, then increased by 8.23% to $115344.0 in 2024, then plunged by 36.62% to $73102.0 in 2025.
- The last three Non-Current Debt figures came in at $73102.0 (Q3 2025), $96264.0 (Q1 2025), and $115344.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 14.02 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 9.05 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 3.92 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.48 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 569.60 Mn |
| 10 | China SXT Pharmaceuticals | 187.96 Mn | 166.77 Mn | - | 73,102.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 73,102.00 |
| Sep 30, 2025 | 73,102.00 |
| Mar 31, 2025 | 96,264.00 |
| Mar 31, 2025 | 96,264.00 |
| Sep 30, 2024 | 115,344.00 |
| Sep 30, 2024 | 115,344.00 |
| Mar 31, 2024 | 117,129.00 |
| Mar 31, 2024 | 117,129.00 |
| Sep 30, 2023 | 106,575.00 |
| Sep 30, 2023 | 106,575.00 |
| Mar 31, 2023 | 117,862.00 |
| Mar 31, 2023 | 117,862.00 |
| Mar 31, 2021 | 6,292.00 |
| Mar 31, 2021 | 6,292.00 |
| Sep 30, 2020 | 15,213.00 |
| Sep 30, 2020 | 15,213.00 |
| Mar 31, 2020 | 36,511.00 |
| Mar 31, 2020 | 36,511.00 |
| Sep 30, 2019 | 55,052.00 |
| Sep 30, 2019 | 55,052.00 |